Table 3.

Selected ongoing phase II/III studies with PARP inhibitors in gBRCA1/2m early-stage breast cancer

Study	Disease	Phase	N	Treatment	Status
OlympiA NCT0203282392	gBRCA1/2m with either TNBC or ER+ and/or PgR+ and HER2-negative BC	III	1500 (est)	Olaparib tablets vs placebo after surgery and at least 6 cycles of neoadjuvant or adjuvant chemotherapy	ONGOING
NCT0228234591	gBRCA1/2m stage I–III BC ≥1 cm, HER2-negative	II	36	Neoadjuvant talazoparib 1 mg (monotherapy) up to 6 months	ONGOING
BRE09-146 NCT0107497093	TNBC or gBRCA1/2m HER2-negative BC with residual disease after neoadjuvant chemotherapy	II	135	Cisplatin IV every 21 days for 4 cycles vs cisplatin (same dose) plus rucaparib on days 1, 2, 3 every 21 days for 4 cycles	ONGOING

BC breast cancer, ER+ oestrogen receptor-positive, est estimated, gBRCA1/2m germline BRCA mutation, HER2 human epidermal growth factor receptor 2, PgR+ progesterone receptor-positive, TNBC triple-negative BC